Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.59
+0.47 (+0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
55
56
Next >
The Top Healthcare Stocks to Buy With $100
January 23, 2023
Don't overlook these big-name foreign healthcare stocks.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
January 20, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
January 19, 2023
After years of lab failures, the companies could crack open a multibillion-dollar market.
Via
Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
January 19, 2023
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key...
Via
Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
January 19, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
AbbVie Stock: Dividend King ABBV Overview
January 19, 2023
Via
MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
January 18, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
January 18, 2023
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
January 14, 2023
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...
Via
Talk Markets
The Viral “Tripledemic” Opportunity
January 14, 2023
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu...
Via
Talk Markets
3 Growth Stocks Poised for Huge Gains in 2023
January 14, 2023
These big pharmaceuticals are poised for back-to-back big years.
Via
The Motley Fool
Why These Two Biotech Stocks Blasted Higher This Week
January 13, 2023
There's nothing like a big-premium buyout to send a company's share price to the moon.
Via
The Motley Fool
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
January 13, 2023
Sharp Tesla price cuts and some notable earnings were in focus.
Via
Investor's Business Daily
Could This New Drug Launch Be a Hit for Viatris?
January 12, 2023
Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort.
Via
The Motley Fool
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
January 11, 2023
Via
Benzinga
AIRSUPRA™ (PT027) approved in the US for asthma
January 11, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout
January 10, 2023
CinCor will bolster AstraZeneca's growing cardio-renal business.
Via
Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
January 10, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion
January 09, 2023
CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments
Via
Spotlight Growth
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal
January 09, 2023
AstraZeneca stock wavered as it agreed to buy CinCor Pharma, maker of blood pressure drug baxdrostat for $1.8 billion. CINC stock soared.
Via
Investor's Business Daily
Why Is CinCor (CINC) Stock Up 138% Today?
January 09, 2023
CinCor (CINC) stock is rocketing higher on Monday following news that AstraZeneca (AZN) is acquiring the company for up to $1.8 billion.
Via
InvestorPlace
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
January 09, 2023
Bloomberg
Via
Benzinga
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline
January 09, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 09, 2023
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
Via
InvestorPlace
1 Stock Defying the Downturn to Buy, and 1 to Avoid
January 06, 2023
These two stocks might go in different directions in the future.
Via
The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
January 05, 2023
Via
Benzinga
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
January 05, 2023
From
Tempus
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
AstraZeneca Stock Scores Relative Strength Rating Upgrade
January 04, 2023
AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.